Archives
-
Isochlorogenic acid A: From Molecule to Model
2026-09-01
Isochlorogenic acid A research spans solvent-aware small-molecule assays and engineered wound-repair systems. This guide explains how 3,5-Dicaffeoylquinic acid formulation, controls, and biological endpoints should be interpreted together.
-
Dextrose in Hypoxia and Immunometabolism
2026-09-01
Learn how to use Dextrose (D-glucose) as a controlled nutrient variable in hypoxia, tumor–immune co-culture, and cellular energy production assays. This workflow combines practical preparation guidance, factorial experimental design, and troubleshooting for more reproducible glucose metabolism research.
-
Carbapenemase Gene Transmission in CREC
2026-08-31
A 2025 BMC Microbiology study integrated resistance-gene localization, plasmid-transfer testing, mobile-element profiling, and strain typing to characterize carbapenem-resistant Enterobacter cloacae across eight teaching hospitals in Guangdong. Its findings identify plasmid-associated blaNDM-1 and efficient horizontal dissemination as major concerns for antimicrobial resistance research, while also showing substantial multidrug resistance among carbapenemase-gene-positive isolates.
-
γH2AX DNA Damage Detection Kit Workflow
2026-08-31
Turn radiation, drug, and genotoxicity experiments into spatially resolved DNA double-strand break measurements with a red γ-H2AX immunofluorescence workflow. The assay connects radiosensitizer screening, apoptosis studies, and DNA repair research while providing practical controls, quantitative readouts, and troubleshooting guidance.
-
Ferrostatin-1: Practical Ferroptosis Assay Guide
2026-08-30
Ferrostatin-1 (Fer-1) turns ferroptosis from a suspected endpoint into a testable causal mechanism by rescuing cells from lipid-peroxidation-driven injury. This workflow shows how to pair Fer-1 with RSL3 or erastin, redox readouts, and NF-κB/PTGS2 analysis in melanocyte, cancer, and neurodegeneration studies.
-
MRTFA–KCNMB1 Control of Cancer Cell Stiffness
2026-08-29
The reference study identifies potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. By combining mechanical, electrophysiological, immune-cytotoxicity, transcriptomic, and mouse-model approaches, it shows that BK-channel activation can stiffen cancer cells, improve lymphocyte-mediated killing, and reduce metastatic colonization.
-
EGCG Nanoparticles Enhance FLASH Radiotherapy
2026-08-28
Xu and colleagues developed functionalized self-assembled EGCG nanoparticles, termed BENPs, to increase tumor sensitivity to FLASH-RT while preserving the modality’s normal-tissue rationale. In a 4T1-based study, BENPs enhanced radiation-associated ROS and DNA damage, promoted tumor-cell death, and stimulated antitumor immune features, although further validation is needed before clinical translation.
-
Kir4.1–Panx3 Signaling in Orofacial Neuropathic Pain
2026-08-28
Feng et al. identify a trigeminal ganglion Kir4.1–Panx3 signaling axis in chronic constriction injury of the infraorbital nerve, linking satellite glial potassium-channel loss with reactive oxygen species and p38 MAPK activity. Genetic knockdown, overexpression, cellular experiments, and rescue studies support Panx3 as a downstream mediator of orofacial mechanical allodynia, while also revealing context-dependent signaling behavior that warrants further validation.
-
Nile Red Workflows for Lipid Droplet Analysis
2026-08-27
Nile Red enables practical intracellular lipid droplet staining with a dual-channel strategy that separates droplet-selective green fluorescence from broader red lipid-associated signal. This guide translates findings from an autophagy–lipid accumulation study into assay design, imaging, quantitative analysis, and troubleshooting workflows.
-
BRD4–TXNIP Signaling Sensitizes Tumors to Ferroptosis
2026-08-27
The reference study identifies a TXNIP-centered mechanism by which BRD4 inhibition suppresses histone H4 UFMylation, weakens c-MYC chromatin activity, and increases ferroptosis sensitivity in solid cancer cells. Its findings provide a mechanistic rationale for combining a BET bromodomain inhibitor with ferroptosis-inducing strategies while highlighting the risk that BRD4 inhibition may produce quiescent, drug-tolerant cells rather than complete tumor eradication.
-
Ceftolozane Sulfate: From Mechanism to Translation
2026-08-26
A translational framework for using Ceftolozane sulfate in mechanism-led susceptibility testing, PK/PD studies, resistant-pathogen modeling, and clinically relevant experimental design.
-
DMG-PEG2000-NH2: From Chemistry to LNP Assays
2026-08-26
DMG-PEG2000-NH2 is an NH2-PEG derivative for controllable bioconjugation in liposomes and lipid nanoparticles. This guide connects linker chemistry with orthogonal assay design, using a tuberculosis drug-discovery study to show how researchers can distinguish genuine functional improvement from a single favorable readout.
-
Hypoxia and Immunometabolism in Tumor Microenvironments
2026-08-25
This 2025 Cancer Letters review integrates tumor hypoxia, metabolic competition, and immune dysfunction into a dynamic model of immunosuppressive tumor microenvironment formation. Its main practical value is identifying linked metabolic and oxygen-sensing processes that may guide tumor-targeted interventions while clarifying why simplified culture systems may not reproduce the full biology.
-
Ciprofloxacin as a Precision Assay Probe
2026-08-25
Ciprofloxacin is more than a benchmark fluoroquinolone antibiotic: it can serve as a mechanistic probe for linking DNA damage, formulation behavior, ultrasound activation, and immune readouts. This article translates a 2026 ZIF-8 nanotheranostic study into practical assay-design decisions while preserving the compound’s core antibacterial relevance.
-
Reversine: Aurora Kinase Inhibitor Workflow
2026-08-24
Reversine is an Aurora kinase inhibitor for controlled perturbation of Aurora A, B, and C activity in mitosis-focused cell and cancer research assays. This guide covers solvent preparation, assay controls, QC, and interpretation boundaries; it should not be used to infer clinical efficacy, therapeutic dosing, or diagnostic performance.